Moderna slashes research spending, trims pipeline as it looks to regain footing | Morningstar
Moderna plans to file for three vaccine approvals by year-end, cutting R&D spending by 20% and dropping five drug candidates from its pipeline. The company aims for 10 approvals by 2027, focusing on critical vaccines like next-gen COVID, flu-COVID combo, and RSV for high-risk adults under 60.
Reference News
Moderna forecasts $2.5-$3.5 billion in sales for 2024, with 25% annual revenue growth from 2026-2028 driven by new product launches. The company plans to submit an FDA application to expand RSV shot approval to high-risk adults under 60, and is focusing on a COVID-flu combination shot. Moderna's mRESVIA met immune-response targets in a new study, and the company plans to launch a flu vaccine efficacy study this year.
Moderna to cut five clinical programs, aiming to reduce $1.1bn in R&D costs, focusing on expanding commercial portfolio into oncology, rare diseases, and non-respiratory vaccines. The strategy targets ten product approvals over three years, including vaccines for Covid-19, flu, and melanoma. Despite positive Phase III results for mRESVIA in 18–59-year-olds, investor response remains tepid, reflecting Moderna's challenges post-Covid-19 pandemic.
Moderna announces 10 product approvals by 2027, including next-gen COVID and flu/COVID combo vaccines for 2024 submission, positive Phase 3 results for RSV vaccine for high-risk adults, and norovirus vaccine advancing to Phase 3. The company plans to reduce R&D expense by $1.1 billion and extend financial framework through 2028.
Moderna plans to file for three vaccine approvals by year-end, cutting R&D spending by 20% and dropping five drug candidates from its pipeline. The company aims for 10 approvals by 2027, focusing on critical vaccines like next-gen COVID, flu-COVID combo, and RSV for high-risk adults under 60.